A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Study Details
Study Description
Brief Summary
Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Patients treated with Prednisone Prednisone will be administered for three days before starting RT, and during the first three fractions of RT. Following an interim analysis of the decrease in sTNFR1 level, a decision will be made whether to administer prednisone for seven days prior to RT, and to continue for additional seven days during RT. |
Drug: Prednisone
Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
|
Outcome Measures
Primary Outcome Measures
- Mitigation of liver inflammation as reflected by sTNFR1 levels [at baseline, day of first RT fraction, day of 3rd RT fraction and at 1-, 3- and 6-months post commencing radiation therapy]
Measuring whether sTNFR1 level is attenuated following prednisone treatment, given before and during radiation therapy for HCC patients who are at high risk of radiation induced liver toxicity. sTNFR1 levels will be summarized descriptively at each time point as absolute values and change from baseline (prior to taking prednisone). Longitudinal regression models will be used to test whether mean changes over time are statistically significant. Treatment with prednisone will be considered successful if it causes a decrease in the level of sTNFR1 of 50%, which would be predicted to decrease toxicity by 15%.
Secondary Outcome Measures
- Estimating the safety of the steroid treatment [up to 6 weeks from start of study treatment]
Define steroid administration protocol based on the rate of drug-related grade 3-5 adverse events attributable to the study drug and experienced within the first 6 weeks of study treatment. These will be assessed via NCI's CTCAE version 5.0. Toxicity rates for patients on this study will be compared to a propensity matched historical control cohort of recently treated patients at UM who were not treated with prednisone.
- Percent of patients who complete of the proposed steroid treatment [up to 6 weeks from start of study treatment]
Successful completion of steroid treatment.
- Evaluate whether steroid treatment reduces radiation-induced liver toxicity [up to 6 weeks from start of study treatment]
Rate of liver decompensation (as measured by worsening in ALBI score>0.5) or grade 3-5 GI bleeding during the subsequent 6 months following radiation treatment. The former are laboratory values that are already collected as part of standard of care. The latter will be assessed via the NCI CTCAE version 5.
- Assess whether steroids have a durable ability to attenuate the level of inflammation as reflected by sTNFR1 level [up to 6 months from start of study treatment]
Determining the mitigation of the inflammatory state, as reflected by biomarkers previously proposed in the literature to correlate with radiation-induced liver injury.
- Assess tumor response [up to 6 months from start of study treatment]
assessing tumor response as part of standard of care to determine response rate
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with hepatocellular carcinoma are eligible for this trial. Hepatocellular carcinoma is defined as having at least one of the following:
-
Biopsy proven hepatocellular carcinoma (HCC); or
-
A discrete hepatic tumor(s) as defined by the AASLD criteria (80) - for cirrhotic patients, >1cm with arterial hypervascularity and venous or delayed phase washout on contrast enhanced CT or MRI.
-
Patients must have recovered from the acute effects of prior liver-directed therapy (e.g., RT, RFA, or TACE), and a minimum of 4 weeks must have passed since the last procedure and protocol therapy.
-
Patients must have a performance status of ≤2.
-
Patients must be 18 years of age or older.
-
Patients with at least one of the following:
-
ALBI score equal to (-1.81) or higher (worse). This value was calculated as the equivalent ALBI score for CP score equal 7 in Cousins et al study's cohort(59).
-
Lesion(s) with a cumulative treatment diameter of ≥ 4cm.
-
CP score equal to 7 or higher (worse).
- Patients must understand and be willing to sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risks.
Exclusion Criteria:
-
Any serious disease, comorbidity or intercurrent illness which precludes delivery of radiation therapy, as determined by the treating investigator.
-
Any contraindication to the administration of steroids, including
-
Documented hypersensitivity to prednisone or any component of the formulation.
-
Systemic fungal infection.
-
Patients with uncontrolled infections or with chronic infections requiring antibiotics.
Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
-
Uncontrolled hyperglycemia.
-
Patients with insulin -dependent diabetes.
-
Patients with decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage.
-
Active gastrointestinal bleeding within 30 days of enrollment.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of Michigan Rogel Cancer Center
Investigators
- Principal Investigator: Theodore Lawrence, University of Michigan Rogel Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UMCC 2022.120